FocusCancer

Are Accurins the cure for Aurora kinase inhibitors?

Science Translational Medicine  10 Feb 2016:
Vol. 8, Issue 325, pp. 325fs4
DOI: 10.1126/scitranslmed.aaf1417

You are currently viewing the abstract.

View Full Text

Via your Institution

Log in through your institution

Log in through your institution


Abstract

A nanoparticle formulation of an Aurora B inhibitor increases antitumor efficacy and reduces toxicity, which may be a precedent for the use of this technology with other small molecules (Ashton et al., this issue).

View Full Text